Harmony Biosciences Holdings, Inc. (HRMY)
| Market Cap | 2.21B |
| Revenue (ttm) | 109.45M |
| Net Income (ttm) | -73.18M |
| Shares Out | 30.21M |
| EPS (ttm) | -2.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $38.82 |
| Previous Close | $38.61 |
| Change ($) | 0.21 |
| Change (%) | 0.54% |
| Day's Open | 38.27 |
| Day's Range | 38.11 - 39.08 |
| Day's Volume | 91,571 |
| 52-Week Range | 30.96 - 51.34 |
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 17, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...
WAKIX ® (pitolisant) Total Revenue of $45.6 Million for Third Quarter of 2020
PLYMOUTH MEETING, Pa. and CHICAGO, Nov. 11, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...
PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 28, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...
PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commerciali...
PLYMOUTH MEETING, Pa. and CHICAGO, Aug.
PLYMOUTH MEETING, Pa. and CHICAGO, Aug.
U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week
Harmony shares began trading on the Nasdaq Global Market under the ticker symbol "HRMY" on August 19, 2020.
Harmony Biosciences: Interesting Pharmaceutical Public Offering
PLYMOUTH MEETING, Pa. and CHICAGO, Aug. 18, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies f...
About HRMY
Harmony Biosciences Holdings, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
| Industry Biotechnology | IPO Date Aug 19, 2020 |
| CEO John Charles Jacobs M.B.A. | Employees 150 |
| Stock Exchange NASDAQ | Ticker Symbol HRMY |
Analyst Forecasts
According to 3 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 33.95% from the latest price.